After the development of RLN2-secreting CAR-T cells and validation of their MMP-inducing capacity in various cancer cell lines and CAR-T cells in vitro, along with their basic phenotypes, we established and evaluated a stromal barrier model of subcutaneous tumors derived from various pancreatic cancer cell lines. The gene discussed is RLN2; the disease is familial pancreatic carcinoma.